Sumário da prevenção da trombose venosa profunda na artroplastia total do joelho

Julio Cesar Gali, Phelipe Augusto Cintra da Silva

Resumo


Os autores descrevem uma atualização sucinta dos principais métodos de prevenção da trombose venosa profunda depois da artroplastia total do joelho, divididos em mecânicos e farmacológicos. Relatam as principais drogas utilizadas, sua dosagem, riscos e benefícios comparativos.


Palavras-chave


próteses e implantes; artroplastia do joelho; trombose venosa; procedimentos cirúrgicos eletivos; complicações pós-operatórias.

Texto completo:

PDF

Referências


White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158(14):1525-31.

Barrack RL. Current guidelines for total joint VTE prophylaxis: dawn of a new day. J Bone Joint Surg Br. 2012;94(11 Suppl A):3-7. DOI: 10.1302/0301-620X.94B11.30824

Parvizi J, Jacovides CL, Bican O, Purtill JJ, Sharkey PF, Hozack WJ, et al. Is deep vein thrombosis a good proxy for pulmonary embolus? J Arthroplasty. 2010; 25(6 Suppl):138-44. DOI: 10.1016/j.arth.2010.05.001

Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746-7. DOI: 10.2106/JBJS.9408.ebo746

Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25(7):1053-60. DOI: 10.1016/j.arth.2009.06.021

Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW. Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. J Arthroplasty. 2008;23(6 Suppl 1):20-4. DOI: 10.1016/j.arth.2008.05.018

Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:175-80. DOI: 10.1097/01.blo.0000238822.78895.95

Parvizi J, Huang R, Restrepo C, Chen AF, Austin MS, Hozack WJ, et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: a preliminary analysis. J Bone Joint Surg Am. 2017;99(2):91-8. DOI: 10.2106/JBJS.16.00147

Liu F, Chu X, Huang J, Tian K, Hua J, Tong P. Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention. Arch Orthop Trauma Surg. 2014;134(5):679-83. DOI: 10.1007/s00402-014-1939-2

Arsoy D, Giori N, Woolson S. Mechanical compression reduces readmissions and wound complications from low molecular weight heparin after total hip or knee arthroplasty. In: AAOS 2017 Annual Meeting. San Diego: American Academy of Orthopaedic Surgeons; 2017.

Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345(18):1305-10. DOI: 10.1056/NEJMoa011099

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-86. DOI: 10.1056/NEJMoa076016

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014;26(10):157-67. DOI: 10.2147/VHRM.S54714.eCollection 2014

Bloch BV, Patel V, Best AJ. Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. Bone Joint J. 2014;96-B(1):122-6. DOI: 10.1302/0301-620X.96B1.31569

Yoshida RA, Yoshida WB, Rollo HA. Novos anticoagulantes orais para a profilaxia e tratamento do tromboembolismo venoso em cirurgias ortopédicas de grande porte. J Vasc Bras. 2011;10(2):145-53. DOI: http://dx.doi.org/10.1590/S1677-54492011000200009

Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012;94(2):257-64. DOI: 10.1302/0301-620X.94B2.27850

Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675. DOI: 10.1136/bmj.e3675

Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgrad Med. 2013;125(4):141-53. DOI: 10.3810/pgm.2013.07.2686.

Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, et al. Edoxaban versus enoxaparin for thrombophylaxis after total knee arthoplasty: the STARS E-3 trial. Thromb Res. 2014;134(6):1198-204. DOI: 10.1186/s12959-016-0121-1

Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, et al.; EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1):68-76.

Li J, Halaszynski T. Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions. Local Reg Anesth. 2015;8:21-32. DOI: 10.2147/LRA.S55306.eCollection 2015

Parvizi J, Hozack WJ, Arnold WV, Huang R, Raphael I, Rothman RH. Pulmonary embolism following total joint arthroplasty: when do they occur? In: AAOS 2012 Annual Meeting. Chicago: American Academy or Orthopaedic Surgeons; 2012.




DOI: https://doi.org/10.23925/1984-4840.2018v20i1a2

Métricas do artigo

Carregando Métricas ...

Metrics powered by PLOS ALM

Apontamentos

  • Não há apontamentos.




Direitos autorais 2018 Revista da Faculdade de Ciências Médicas de Sorocaba. ISSN eletrônico 1984-4840

Licença Creative Commons
Esta obra está licenciada sob uma licença Creative Commons Atribuição 4.0 Internacional.

Apoio: ..............................................................................................................................................

    

Fundação São Paulo - Hospital universitário

 



 

Rev. Fac. Ciênc. Méd. Sorocaba, Sorocaba, SP, Brasil, e-ISSN 1984-4840

A Revista da Faculdade de Ciências Médicas de Sorocaba está licenciada com uma Licença Creative Commons - Atribuição 4.0 Internacional.